What is the upside for 23andMe stock?
On average, they expect 23andMe's stock price to reach 11.50 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View analysts' price targets for 23andMe or view top-rated stocks among Wall Street analysts. Who are 23andMe's key executives? Dr. Jennifer Low, Head of Therapeutics Devel. (Age 52)
Will 23andMe stock rise or fall in 2021 and 2024?
It's difficult to forecast ME stock's short-term price action because it will depend a lot on investor sentiment. In 2024, 23andMe forecasts revenue of $400 million and a gross margin of 58 percent, compared with $247 million and 45 percent in 2021. By 2024, the company hopes to have more than 16 million customers.
Do analysts agree on 23andMe's (23andMe) price target?
The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings. According to analysts' consensus price target of 11.50, 23andMe has a forecasted upside of 54.8% from its current price of 7.43. 23andMe has only been the subject of 2 research reports in the past 90 days.
Should you buy 23andMe (vgac) stock?
VGAC stock has traded at between $9.65 and $18.16 since its debut. It’s currently 6 percent above its low and 44 percent below its peak. As Wall Street hasn’t started covering the stock, analysts haven't yet given it a price target. However, 23andMe's stock forecast looks bullish. 23andMe is a well-funded business.
Is 23 and Me a good investment?
23andMe (ME -5.67%) investors have had a bumpy ride in the last 12 months. The company's shares are down by more than 67%, quarterly revenue growth has slumped into the single digits, and profitability remains far out of reach.
Is me a good stock to buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: ME) stock is to Buy ME stock. Out of 2 analysts, 0 (0%) are recommending ME as a Strong Buy, 1 (50%) are recommending ME as a Buy, 1 (50%) are recommending ME as a Hold, 0 (0%) are recommending ME as a Sell, and 0 (0%) are recommending ME as a Strong Sell.
Why is 23 and ME stock low?
23andMe reported earnings on Nov. 10 with slowing revenue growth. The company is trying to pivot from DNA testing to drug development. The stock is down 34% this year.
Is Resn a buy or sell?
A P/B of 1 means it's selling at its per share book value....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
What stock should a beginner buy?
Summary: Best Stocks To Buy For BeginnersNameSymbolRevenue GrowthAmazonNASDAQ:AMZN13.99%AlphabetNASDAQ:GOOG37.45%AppleNASDAQ:AAPL18.63%CostcoNASDAQ:COST16.56%11 more rows
Which is the best stock to buy?
Biba IPO.Gujarat Polysol IPO.Hemani IPO.Corrtech IPO.Paymate IPO.Rustomjee IPO.Senco Gold IPO.Rainbow IPO.More items...
Is 23andMe profitable?
Although people are increasingly comfortable getting healthcare from startups, the genetics testing retail boom was short and sweet. By summer 2019, DNA test sales started to fall rapidly — 23andMe's revenue declined from $441 million in 2019 to $305 million in 2020.
What is happening with 23andMe?
At the same time, 23andMe has struggled with plummeting revenues and significant losses. It cut 100 employees (or 14% of its staff) in January 2020, before the pandemic, and saw its revenue drop 30% in the year ending March 2020, to $305 million, down from $441 million the previous year, according to company documents.
What company owns 23andMe?
VG Acquisition Corp.23andMe is merging with VG Acquisition Corp., a special purpose acquisition company founded by billionaire Richard Branson, to go public. The deal values the consumer genetic testing company at $3.5 billion, including debt.
Should I sell RESN stock?
There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Resonant stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RESN, but not buy additional shares or sell existing shares.
Will RESN stock go up?
Based on analyst ratings, Resonant's 12-month average price target is $4.50. What is RESN's upside potential, based on the analysts' average price target? Currently there's no upside potential for RESN, based on the analysts' average price target.
Is RESN a good buy?
RESN has a Quality Grade of D, ranking ahead of 7.21% of graded US stocks.
What are the 10 best stocks to buy right now?
Top 10 Stocks To Buy Right NowApple Inc. (NASDAQ: AAPL)Alphabet Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL)Palo Alto Networks, Inc. (NASDAQ: PANW)Shopify Inc. (NYSE: SHOP)Advanced Micro Devices, Inc. (NASDAQ: AMD)Netflix, Inc. (NASDAQ: NFLX)The Walt Disney Company (NYSE: DIS)CrowdStrike Holdings, Inc. (NASDAQ: CRWD)More items...
What Canadian stocks should I buy?
Top Canadian Bank Stock PicksBank NameTickerPrice/Fair ValueThe Toronto-Dominion BankTD0.86%Royal Bank of CanadaRY0.88%Bank of MontrealBMO0.84%Bank of Nova ScotiaBNS0.88%2 more rows•Jul 4, 2022
What stocks do well in a war?
War Stocks to Buy Now According to Hedge FundsIntrepid Potash, Inc. (NYSE:IPI)Lithium Americas Corp. (NYSE:LAC)Northrop Grumman Corporation (NYSE:NOC)Nutrien Ltd. (NYSE:NTR)Lockheed Martin Corporation (NYSE:LMT)
What are the best growth stocks right now?
Fastest Growing StocksPrice ($)EPS Growth (%)Coterra Energy Inc. (CTRA)26.35138.7Marathon Oil Corp. (MRO)22.051,380CF Industries Holdings Inc. (CF)83.32501.42 more rows
Should I buy or sell 23andMe stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 1 hold rat...
What is 23andMe's stock price forecast for 2022?
2 Wall Street analysts have issued 12-month target prices for 23andMe's stock. Their forecasts range from 3.00 to 7.00. On average, they predict 23...
How has 23andMe's stock performed in 2022?
23andMe's stock was trading at 6.66 at the beginning of the year. Since then, ME shares have decreased by 66.8% and is now trading at 2.21. View t...
When is 23andMe's next earnings date?
23andMe is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for 23andMe .
How were 23andMe's earnings last quarter?
23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Thursday, May, 26th. The company reported ($0.16) earnings per share (EPS) for th...
What guidance has 23andMe issued on next quarter's earnings?
23andMe updated its FY 2023 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued reven...
Who are 23andMe's key executives?
23andMe's management team includes the following people: Ms. Anne Wojcicki , Co-Founder, CEO, Pres & Director Mr. Steven J. Schoch , Chief Finan...
Who are some of 23andMe's key competitors?
Some companies that are related to 23andMe include Cerevel Therapeutics (CERE) , Turning Point Therapeutics (TPTX) , Galapagos (GLPG) , Ultrage...
What is 23andMe's stock symbol?
23andMe trades on the NASDAQ under the ticker symbol "ME."
How much money does 23andme get?
As part of its merger with VGAC, 23andMe will get cash proceeds of $759 million, which includes $509 million from the SPAC's trust account and another $250 million as PIPE (private investment in public equity) at $10 per share. 23andMe will use the money for growth.
How much revenue will 23andme have in 2024?
In 2024, 23andMe forecasts revenue of $400 million and a gross margin of 58 percent, compared with $247 million and 45 percent in 2021. By 2024, the company hopes to have more than 16 million customers. Article continues below advertisement.
How much will genetic testing grow in 2025?
Between 2025 and 2027, the global genetic testing market is expected to grow 11.5 percent compounded annually to reach $23 billion. It's difficult to forecast ME stock's short-term price action because it will depend a lot on investor sentiment.
Stock Price Forecast
The 2 analysts offering 12-month price forecasts for 23andMe Holding Co. have a median target of 8.50, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +97.67% increase from the last price of 4.30.
Analyst Recommendations
The current consensus among 2 polled investment analysts is to Buy stock in 23andMe Holding Co.. This rating has held steady since November, when it was unchanged from a Buy rating. Move your mouse over past months for detail
What is the competition of 23andme?
23andMe competitor Natera operates as a diagnostics company. The biotech company offers preconception and prenatal genetic testing services. Natera is expected to generate revenue of $566 million in 2021, and $676 million in 2022.
What is 23andme DNA?
Founded in 2006, 23andMe is a genetics company best known for its in-home DNA testing kits. After the transaction closes, VGAC investors and sponsors will own 13 percent of 23andMe, while PIPE (private investment in public equity) investors will own 6 percent.
How much will the genetic testing market grow in 2027?
The global genetic testing market is expected to grow to $21 billion by 2027 from $12 billion in 2019. Since its inception, roughly 11 million customers have signed up for 23andMe’s services. The company expects its customer base to grow to more than 16 million by 2024.
Is 23andme going public?
23andMe is going public in a SPAC merger with VG Acquisition (VGAC) that values it at $3.5 billion. The transaction is about to close. What's 23andMe's stock forecast after the VGAC SPAC merger? Is the stock a good buy now?
Is 23andme a well funded company?
23andMe is a well-funded business . The genetics company will receive roughly $759 million in gross cash proceeds from the SPAC deal, which includes $250 million in PIPE priced at $10 per share. The PIPE investors include Fidelity, Foresite Capital, Altimeter Capital, and Sir Richard Branson, founder of Virgin Group.
It needs to make money from something bigger than just its genetic test kits
In June, 23andMe ( ME -5.41% ) officially finished the process of going public via a special purpose acquisition company ( SPAC ). These investment vehicles were popular in early 2021, but many have lost value in recent months. This includes 23andMe stock, which currently sits almost 50% below its all-time high.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
These stocks are far from sure things, but their potential is undeniable
First of all, no stock capable of quintupling your money in just over three years is a low-risk investment, so keep that in mind as we go on. And yes, as odd as it may seem, 2025 isn't much more than three years into the future.
The way we buy and sell homes could change dramatically
To put it mildly, the traditional way we buy and sell houses is outdated. It can take months to sell a home, and the process is clunky at best -- there are showings, staging, negotiations, etc. -- and the timeline is up to the buyer and the mortgage lender in most cases.
Don't underestimate the value of data
Most people know 23andMe ( ME -0.81% ) for its consumer-facing genetics testing kits, and while this is certainly an excellent revenue stream, it's not the most exciting part of the company's business.
A social networking stock you might not have considered yet
Technically, Nextdoor isn't public yet, but it has agreed to go public through a special purpose acquisition company (SPAC) deal with Khosla Ventures Acquisition Co. II ( KVSB ), which values the neighborhood-focused social media platform at $4.3 billion.
Prepare for volatility
If you invest in any of these stocks, it's important to mentally prepare yourself for a roller-coaster ride. In fact, since I bought Offerpad in my own portfolio just a few weeks ago, the stock has soared to a high of nearly $21 and has fallen to less than $7.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
23Andme Holding After-Hype Price Prediction Density Analysis
As far as predicting the price of 23Andme Holding at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range.
23Andme Holding Estimiated After-Hype Price Volatility
In the context of predicting 23Andme Holding's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on 23Andme Holding's historical news coverage.
23Andme Holding Stock Price Prediction Analysis
Have you ever been surprised when a price of a company such as 23Andme Holding is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 23Andme Holding backward and forwards among themselves.
23Andme Holding Hype Timeline
As of February 11, 2022 23Andme Holding CO is listed for 4.64. The entity has historical hype elasticity of 0.2 and average elasticity to hype of competition of -2.59. 23Andme is forecasted to increase in value after the next headline with price projected to jump to 5.16 or above.
23Andme Holding Related Hype Analysis
Having access to credible news sources related to 23Andme Holding's direct competition is more important than ever and may enhance your ability to predict 23Andme Holding's future price movements.
23Andme Holding Additional Predictive Modules
Most predictive techniques to examine 23Andme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for 23Andme using various technical indicators.
About 23Andme Holding Predictive Indicators
The successful prediction of 23Andme Holding stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as 23Andme Holding CO, already reflect all publicly available information.
When will 23andme report results?
(Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, August 13, 2021.
What is biotech 2.0?
Biotech 2.0 is here. Big data is an integral part of the drug development process in practically every corner of the industry. In contrast to the labor-intensive, slow, and small-scale nature of the traditional approach to drug development, the biotechs of the future are fusing computing power and laboratory experimentation, and the results will reshape what it means to make new medicines.
Is 23andme going public?
Myles Udland, Brian Sozzi, and Julie Hyman breakdown 23andMe going public with the help of Rich ard Branson, and how the company plans to change its business model to make itself more profitable in the market.
